The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Implications of EGFR expression in MAPK dependency and adaptive immunity status of EGFR-mutated lung adenocarcinoma.
 
Masahiro Torasawa
No Relationships to Disclose
 
Tatsuya Yoshida
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo/UCB Japan; Lilly Japan; MSD Oncology; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai/Roche; Lilly Japan; MSD
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Kouya Shiraishi
No Relationships to Disclose
 
Shigehiro Yagishita
Consulting or Advisory Role - MSD
Speakers' Bureau - LSI Medience Corporation
Patents, Royalties, Other Intellectual Property - TOSOH co. ltd
 
Yuji Uehara
No Relationships to Disclose
 
Jun Miyakoshi
No Relationships to Disclose
 
Ryoko Inaba Higashiyama
No Relationships to Disclose
 
Akifumi Mochizuki
No Relationships to Disclose
 
Yuji Matsumoto
Research Funding - Hitachi Chemical
Expert Testimony - TUITIVE
 
Yuki Shinno
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical
Consulting or Advisory Role - Janssen
Research Funding - Bayer; Gilead Sciences; Janssen; Japan Clinical Research Operations; Merck; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yusuke Okuma
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical
 
Yasushi Goto
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/UCB Japan; Guardant Health AMEA; Janssen; Lilly Japan; Merck; MSD; Nichiiko; Novartis; Ono Pharmaceutical; Pfizer; Sandoz; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health AMEA; Janssen; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Amgen BioPharama (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/UCB Japan (Inst); EP Croit Co. (Inst); EPS Holdings (Inst); Genomic Health (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Preferred Network (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Cancer Net Japan; JAMT
 
Hidehito Horinouchi
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Novocure; Seagen; Yuhan
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BMKK (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Ryuji Hamamoto
No Relationships to Disclose
 
Noboru Yamamoto
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Healios; Merck; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); InventisBio (Inst); Janssen (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Rakuten Medical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst)
 
Shun-ichi Watanabe
No Relationships to Disclose
 
Yasushi Yatabe
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; MSD K.K
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; MSD K.K
Research Funding - Konica Minolta; Merck; Thermo Fisher Scientific
 
Kazuhisa Takahashi
Honoraria - Amgen; AstraZeneca; AstraZeneca; BioMerieux Japan Ltd.; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Eisai; Kyorin; Kyorin; Lilly Japan; MSD K.K; MSD K.K; Nippon Boehringer Ingelheim; Nippon Boehringer Ingelheim; Nippon Kayaku; Nippon Kayaku; Nobelpharma; Novartis; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Pfizer; Sawai Pharmaceutical Co; Sawai Pharmaceutical Co; Shionogi; Shionogi; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Thermo Fisher Scientific; Viatris
Speakers' Bureau - AstraZeneca; Chugai Pharma; Chugai Pharma; Kyorin; Novartis; Ono Pharmaceutical
Research Funding - Chugai Pharma; Chugai Pharma; MSD K. K.; MSD K.K; Ono Pharmaceutical; Ono Pharmaceutical
 
Takashi Kohno
Consulting or Advisory Role - Lilly Japan
Speakers' Bureau - Lilly Japan; Lilly Japan
Research Funding - Chugai Pharma; Guardant Health; Konica Minolta; Sysmex
Patents, Royalties, Other Intellectual Property - Patent fee from Foundation Medicine Inc; Patent fee from Riken Genesis/Amoy Diagnostics; Patent fee from ThermoFisher Scientific
 
Yuichiro Ohe
Leadership - JCOG; JSMO
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Anheart Therapeutics; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; PharmaMar; PharmaMar; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Janssen (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)